INTRODUCTION
Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder characterized by senile plaques enriched with b-amyloid (Ab) peptides and neurofibrillary tangles comprised of hyperphosphorylated tau (Selkoe and Hardy, 2016) . Oligomeric forms of Ab (oAb) are believed to trigger a pathological cascade leading to AD (Selkoe and Hardy, 2016) . Recent genome-wide association studies have identified numerous genetic loci altered in AD (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2013) , which may not impact directly on Ab generation or tau aggregation. Interestingly, a subset of these genes, including TREM2 (Triggering Receptor Expressed on Myeloid cells 2), CD33, CR1, MS4A, ABCA7, and EPHA1, is expressed in myeloid cell types such as microglia, suggesting that immune cell dysfunction may play a key role in AD pathogenesis (Efthymiou and Goate, 2017) . In addition to familial b-amyloid precursor protein (APP), presenilin (PS) 1/2 alleles linked to early AD onset (Vetrivel et al., 2006) , variations in ApoE (ε4), and the TREM2 ectodomain (R47H) are currently associated with the highest risk of AD (Guerreiro and Hardy, 2013; Jonsson et al., 2013) . Additional variants of the TREM2 ectodomain-e.g., R62H-are also linked to increased AD risk (Jin et al., 2014) . TREM2 has been shown to mediate phagocytic clearance of apoptotic cell debris and modulate inflammatory response (Doens and Ferná ndez, 2014; Jay et al., 2017b; Kleinberger et al., 2014) . TREM2 binds to its adaptor, DNAX-activating protein of 12 kDa (DAP12) on the surface of microglia to enact innate immune responses and downstream cellular responses or signaling pathways (Jay et al., 2017b) . Despite recent identification of lipids and ApoE as TREM2 ligands (Atagi et al., 2015; Wang et al., 2015; Yeh et al., 2016) , biological ligands for TREM2 and their consequent impact on microglial function in AD pathogenesis remain unclear.
RESULTS

TREM2 Binds to Ab Oligomers
To determine whether TREM2 could function as a receptor for Ab, we prepared synthetic Ab 1-42 monomers and oligomers (Figures S1A and S1B) using protocols previously reported , and we investigated whether the TREM2 ectodomain (TREM2-Fc) could bind to Ab. TREM2-Fc co-precipitated with oAb and, to a much lesser extent, with Ab monomers; minimal binding was observed with TREM1-Fc or Fc controls (Figures 1A, 1B, and S1C) . Immobilized TREM2-Fc bound to oAb with an affinity comparable to previously described Ab receptor proteins, such as CD36-Fc and RAGE-Fc ( Figure 1C) , with TREM2-Fc exhibiting little binding with Ab monomers (data not shown). Similarly, immobilized oAb bound TREM2-Fc with a comparable affinity to CD36-Fc and RAGE-Fc ( Figure 1D ), with little interaction detected in Fc and TREM1-Fc controls. Bio-layer interferometry assays consistently demonstrated high-affinity Ab interactions with TREM2-His (K D = 12.7 ± 0.5 nM) ( Figure 1E ), where TREM1-His showed minimal oAb binding ( Figure 1F ). We also confirmed Ab/TREM2 interactions using surface plasmon resonance (SPR) assays ( Figure S1D ).
Interestingly, TREM2 R47H or R62H mutation compromised TREM2-Fc interactions with oAb in solid phase-binding assays ( Figure 1G ). In agreement with these results, increased oAb binding was observed in microglia-derived BV2 cells with stable TREM2 overexpression ( Figure 1H ), where TREM2 mRNA and Representative images (A) and quantified densitometric analysis (B) . All values were normalized to input. M, marker; n = 5 independent experiments; ***p < 0.001 by unpaired t test. (C) Levels of biotin-oAb 1-42 bound to immobilized Fc/Fc-fusion proteins were normalized to maximal Ab/TREM2-Fc interactions. n = 3 independent experiments. (D) Levels of Fc/Fc-fusion proteins bound to immobilized biotin-oAb 1-42 were normalized to maximal TREM2-Fc/Ab binding. n = 3 independent experiments. (E and F) Bio-layer interferometry-binding kinetics of TREM2-His (E) or TREM1-His (F) incubated with immobilized biotin-oAb (curves correspond to His-tagged proteins with the following concentrations: 222.2 nM [top] and 74.1, 24.7, 8.23, and 2.74 nM [bottom] ; in E and F). (G) Maximal levels of biotin-oAb 1-42 bound to immobilized wild-type (WT) TREM2-Fc and R47H and R62H mutants (normalized to WT). n = 3 independent experiments; **p < 0.01, one-way ANOVA followed by Dunnett's post hoc test. (H) Representative images of biotin-oAb 1-42 (red) bound to BV2 cells overexpressing TREM2 or BV2 control (DAPI, blue; scale bar, 10 mm). n = 5 independent experiments; **p < 0.01, unpaired t test. (I and J) Levels of Ab 1-42 co-precipitated with TREM2 in lysates from APP transgenic TgCRND8 mice (I) or human AD brains (J) were determined by ELISA. Bound Ab was normalized to the IgG control from each sample (n = 5 for TgCRND8, n = 6 for human AD). All values represent mean ± SD. See also Figure S1 and Table S1. protein levels were determined to be elevated to almost 3-fold and 2.5-fold, respectively (Figures S1E and S1F), compared to BV2 controls. Likewise, TREM2 also co-immunoprecipitated with Ab in BV2 cells incubated with oAb ( Figure S1G ). Importantly, an endogenous Ab/TREM2 complex was co-immunoprecipitated from AD mouse brain lysates (TgCRND8, overexpressing mutant human APP) ( Figure 1I ) and human AD brain lysates (Figures 1J and S1H-S1J). Although we were unable to differentiate binding of Ab monomers from oligomers in our assays, we anticipate that TREM2 interacts preferentially to oAb, as seen in our in vitro-binding assays.
TREM2 Regulates Ab Degradation and Ab-Induced Depolarization in Microglia
We next determined whether TREM2 could modulate microglial Ab catabolism. Given that a variety of Ab surface receptors are redundantly expressed in microglia (Doens and Ferná ndez, 2014) , it was not surprising that TREM2 deletion had little effect on surface binding ( Figure S2A ) and phagocytic uptake of Ab in microglia ( Figure 2A ). However, we found that TREM2-deficient microglia showed significantly reduced Ab degradation; fluorescent dye FAM-labeled Ab was largely cleared 2-4 hr after internalization in wild-type (WT), but it was mostly retained in TREM2 knockout (KO) microglia ( Figures 2B-2D ). Although Ab degradation was inhibited by exposure to the proteasomal inhibitor MG132, only partial effects were observed using a lysosomal/autophagy inhibitor (chloroquine [CQ] ) (Figures 2C and 2D) . These results were confirmed by ELISA using unlabeled oAb ( Figure S2B ). In agreement with partial effects in Ab turnover with CQ, only a small fraction of Ab was found in LAMP1-positive compartments ( Figure S2C ). These results indicate that TREM2 mediates Ab catabolism largely through proteasomal degradation pathways. Indeed, it is widely accepted that proteasome and lysosome pathways are interconnected through autophagosomes (Kwon and Ciechanover, 2017) . How TREM2 is involved in proteasome-and/or lysosome-mediated Ab degradation warrants further examination. We also determined whether TREM2 deletion affects turnover rates of ligands for other microglial receptors, such as Gas6, which has been previously reported to bind to the MerTK receptor (Chen et al., 1997) . We found little or no Gas6 binding to TREM2 ( Figure S2D ); fluorescent-labeled Gas6 featured slower turnover rates compared to Ab, where WT and TREM2 KO microglia showed no differences in Gas6 degradation ( Figure S2E ). Together, these data support a specific role for TREM2/Ab interactions in Ab degradation.
Next, we characterized electrophysiological effects of oAb on microglial membranes in culture. Induction of potassium (K + ) currents by oAb has been shown to promote microglial membrane depolarization (Franciosi et al., 2006) . We observed significant depolarization and associated changes in resting membrane potential (RMP) with oAb treatment and TREM2 deletion; however, oAb failed to induce further changes in membrane potential with TREM2 deletion ( Figure 2E ). Blocking either Kv1.3 or Kir3.1 channels eliminated the effect of TREM2 deficiency on RMP ( Figure S2F ). The presence of K + currents in microglia is an early indicator of microglial activation associated with increased microglial excitability, proliferation, chemotaxis, and migration Figure S2 .  or Arg1 expression was determined by qRT-PCR in WT or TREM2 KO microglia in the presence or absence of 1 mM Ab. n = 3 independent experiments; *p < 0.05 and **p < 0.01, two-way ANOVA followed by Tukey's post hoc test.
(B and C) Cytokine levels in conditioned media from WT or TREM2 KO microglial cultures treated with oAb 1-42 for 24 (B) or 48 hr (C) were quantified by ELISA. All values were normalized to WT-Ab (0 mM) levels for each time point. n = 3 independent experiments; *p < 0.05, **p < 0.01, and ***p < 0.001, two-way ANOVA followed by Tukey's post hoc test.
(legend continued on next page) (Boucsein et al., 2000; Lam and Schlichter, 2015) . We then characterized K + inward current induction and observed similar changes as seen in membrane potential above ( Figures  2F-2H ). Since TREM2 KO microglia did not show a corresponding decrease in cell capacitance ( Figure S2G ), the effect of TREM2 deficiency on K + inward current was not due to decreased membrane surface area in TREM2 KO microglia. Together, this suggests a role for TREM2 in mediating oAb-dependent changes in microglial excitability through K + inward currents, and it provides functional evidence for the significant downregulation of K + channels, such as Kir4.1 (KCNJ10), Kir7.1 (KCNJ13), and Kir 5.1 (KCNJ16), in TREM2-deficient microglia, as described previously (Ulland et al., 2017; Wang et al., 2015) . Given the central role inwardly rectifying K+ channels play in RMP and transition from resting to activated states, reduced expression of functional K + channels is a key contributing factor to the depolarized RMP observed in TREM2-deficient microglia.
TREM2 Deficiency Alters Ab-Induced Cytokine Expression, Secretion, and Downstream Signaling Microglia are critical mediators of the inflammatory response in brain. We observed increased expression of proinflammatory cytokines, such as interleukin-6 (IL-6) and macrophage inflammatory protein 1 a (MIP-1a, also known as CCL3), and decreased anti-inflammatory Arg1 expression with oAb exposure in WT microglia, whereas Ab-induced effects on cytokine production were abolished in TREM2 KO microglia ( Figure 3A ). Using multiplex ELISA assays, we next examined cytokine secretion profiles from cultured WT and TREM2 KO microglia in the presence or absence of oAb. Exposure to oAb for 24 or 48 hr resulted in significantly elevated secretion of IL-6 and MIP-1a in WT microglia, with little or no oAb-induced change observed in TREM2 KO microglia ( Figures 3B and 3C ). We did not observe any significant oAb-induced changes in IL-1a, IL-4, interferon g (IFN-g), and tumor necrosis factor a (TNF-a) secretion in WT and TREM2 KO microglia; steady-state levels of these cytokines were also equivalent in WT and TREM2 KO microglia ( Figures S3A and S3B ).
As our results suggest that TREM2 mediates Ab-induced microglial response, we next investigated downstream events that potentially drive TREM2-dependent microglial activation. Interestingly, interaction between TREM2 and its obligate adaptor DAP12 was increased in primary microglia with acute Ab exposure (30-60 min), as indicated by fluorescence resonance energy transfer (FRET) assay ( Figure 3D ) and TREM2/ DAP12 co-immunoprecipitation assays ( Figures 3E and S3C ). Overexpression of TREM2 increased DAP12 levels ( Figure S3D ), likely due to stabilizing interactions previously described (Zhong et al., 2015) ; TREM2-DAP12 interactions were further enhanced by oAb treatment ( Figure S3E ). In addition, brief oAb exposure induced SYK phosphorylation (a key component of the TREM2/DAP12-signaling pathway) in WT, but not TREM2 KO, microglia ( Figure 3F ). Overexpression of human TREM2 in a BV2 microglial cell line pretreated with mouse TREM2 small hairpin RNA (shRNA) dramatically increased GSK3b phosphorylation under steady-state conditions, and it further enhanced GSK3b phosphorylation with oAb treatment, while little change was observed with oAb treatment in control BV2 cells lacking human TREM2 ( Figure S3F ). These results indicate that TREM2 is required for downstream signal transduction in response to Ab stimulation.
TREM2 Deficiency Alters Ab Degradation, Microglial Migration, Proliferation, and Apoptosis in Response to Ab In Vivo
We next determined the effects of stereotactic Ab injection in WT and TREM2 KO mouse brain. At 16 hr post-injection, we found a significant decrease in the number of microglia clustering at FAM-Ab-enriched regions in TREM2 KO compared to WT, as indicated by IBA1 immunostaining ( Figures 4A and 4B ), whereas FAM-Ab deposition was similar between WT and TREM2 KO brain at this time point ( Figure 4C ). No microglia clustering was observed in control vehicle-injected WT or TREM2 KO mouse brain ( Figure S4 ). These results suggest that TREM2 deletion attenuates microglial migration in response to acute Ab injection. We next investigated microglial response to extended Ab exposure in WT and TREM2 KO mice. We observed decreased hippocampal Ab clearance in TREM2 KO mice 3 days after oAb injection into the microglia-enriched lacunosum moleculare layer within the hippocampus where fewer neuronal cell bodies are found (Figures 4D and 4E) . This is in good agreement with recent findings that TREM2 modulation may regulate Ab pathology (Yuan et al., 2016) . Upon stereotactic oAb injection, we observed an increase in microglial proliferation (PCNA positivity) and caspase-3 activation in WT mice (Figures 4F and 4G) , indicative of Ab-induced microgliosis and apoptotic cell death, which may occur concurrently (Askew et al., 2017) . Interestingly, TREM2 deletion largely abolished Ab-induced microglial proliferation ( Figure 4F ) and apoptosis ( Figure 4G ). Additionally, microglial process length, previously shown to be associated with microglial activation (Zhong et al., 2017) , was found to be significantly reduced in Ab-injected WT brain, but not in TREM2 KO brain ( Figure 4H ).
Together, our results provide evidence that TREM2/Ab interactions can mediate downstream TREM2/DAP12-signaling pathways, thereby triggering microglial Ab degradation and microglia depolarization, activation, and consequent cytokine (D) BV2 cells overexpressing TREM2-GFP and DAP12-mCherry were treated with or without (1 mM) for 30 min, and interactions between TREM2-GFP and DAP12-mCherry were determined by FRET analysis. White rectangles indicate bleached regions. Scale bar, 10 mm. n = 6 cells per group; **p < 0.01, unpaired t test. (E) Levels of endogenous DAP12 co-precipitated with TREM2 in primary microglia treated with oAb 1-42 were determined by western blot. n = 5 independent experiments; ***p < 0.001, one-way ANOVA followed by Dunnett's post hoc test. (F) Levels of tyrosine-phosphorylated (Y525/526) and total SYK in WT or TREM2 KO microglia treated with oAb (1 mM) were determined by western blot. n = 3 independent experiments; *p < 0.05; n.s., no significance; one-way ANOVA. All values represent mean ± SD. See also Figure S3 . expression/release. TREM2 also drives microglial activation and migration to sites of Ab enrichment in vivo, indicating that TREM2 is an Ab sensor that mediates Ab clearance and Ab-dependent microglia activation and cytokine release.
DISCUSSION
Although a role for TREM2 in AD pathogenesis has been recently proposed, opposing effects on Ab plaque deposition are observed with TREM2 deletion in differing AD models (Jay et al., 2015; Wang et al., 2015) , which may be attributed to differences in genetic backgrounds and/or additional effects derived from APP/PS1 overexpression (Cavanaugh et al., 2014; Lee and Han, 2013) . Interestingly, recent work in an APP/PS1 AD mouse model indicates that TREM2 deletion can reduce Ab plaque load at early (H) Reconstructed 3D microscopy images of IBA1-stained (white) microglia. Average process length per microglia was quantified and shown in the adjacent graph. n = 9-12 mice/group. Scale bar, 10 mm. ***p < 0.001, two-way ANOVA followed by Tukey's post hoc test. All graphs represent mean ± SD. See also Figure S4 .
stages of AD onset yet exacerbates Ab deposition at late stages of onset (Jay et al., 2017a) . As the involvement of TREM2 in Ab-associated pathogenesis is likely complex, a definitive model of how TREM2 contributes mechanistically to Ab pathology and AD pathogenesis has yet to be established. Our work provides pioneering evidence that TREM2 directly interacts with Ab and regulates Ab degradation, and it demonstrates a novel role for TREM2 as a microglial Ab receptor capable of transducing various microglial responses to Ab.
Changes in MIP-1a in response to Ab are particularly interesting: in addition to playing a key role in inflammation, MIP-1a has been shown to promote microglial activation and migration (Wang et al., 2008) . The absence of Ab-induced MIP-1a induction in TREM2 KO microglia may contribute to reduced microglial clustering at Ab deposits. Interestingly, TREM2 deficiency has been recently shown to attenuate microglial migration toward injured neurons (Mazaheri et al., 2017) . Together, our findings demonstrate that TREM2 plays an important role in mediating microglial migration in response to pathological stimuli.
Our observation that AD-associated R47H and R62H mutations compromise interactions between Ab and TREM2 provides a plausible mechanism for TREM2 and its disease-prone genetic variants in AD pathogenesis. Our findings are in good agreement with recent structural analysis predicting that AD-associated TREM2 mutations might compromise a potential TREM2 ligand-binding interface (Kober et al., 2016) . Our previous work and evidence from other groups have identified ApoE and lipids as TREM2 ligands (Atagi et al., 2015; Wang et al., 2015; Yeh et al., 2016) . Since ApoE is the most potent genetic risk factor associated with late-onset AD (Kanekiyo et al., 2014) , together with evidence of dysfunctional lipid metabolism in AD (Di Paolo and Kim, 2011; Walter and van Echten-Deckert, 2013 ), it will be interesting to determine the interplay among ApoE, lipids, and Ab in TREM2 signaling in future studies.
Although our results present evidence that Ab-induced microglial response is in part mediated through TREM2 function, there remains a possibility that Ab effects may be also derived through parallel pathways or through indirect microglial changes with TREM2 deletion. Although TREM2 is not a component of ion channels, our results indicate that TREM2 deletion itself could induce changes in membrane inward current and membrane potential. Thus, although TREM2/Ab interactions likely drive some microglia-modulating effects with Ab exposure, there may also be secondary changes with perturbation resulting from TREM2 deletion that may also modulate Ab-dependent signaling and microglial function. A detailed analysis of the potential significance of alternative pathways and secondary changes is indeed interesting, and it warrants further investigation. As current strategies targeting Ab generation and use of Ab antibody clearance have seen little success, modulation of microglial clearance through receptors such as TREM2 may be a favorable alternative for future pharmacological development.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
DECLARATION OF INTERESTS
The authors declare no competing interests. Zhao, Y., Tseng, I.C., Heyser, C.J., Rockenstein, E., Mante, M., Adame, A., Zheng, Q., Huang, T., Wang, X., Arslan, P. E., et al. (2015) . Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. Neuron 87, 963-975.
Zhong, L., Chen, X.F., Zhang, Z.L., Wang, Z., Shi, X.Z., Xu, K., Zhang, Y.W., Xu, H., and Bu, G. (2015) . DAP12 stabilizes the c-terminal fragment of the triggering receptor expressed on myeloid cells-2 (TREM2) and protects against LPS-induced pro-inflammatory response. J. Biol. Chem. 290, 15866-15877.
Zhong, L., Chen, X.F., Wang, T., Wang, Z., Liao, C., Wang, Z., Huang, R., Wang, D., Li, X., Wu, L., et al. (2017) . Soluble TREM2 induces inflammatory responses and enhances microglial survival. J. Exp. Med. 214, 597-607.
Zhu, B., Jiang, L., Huang, T., Zhao, Y., Liu, T., Zhong, Y., Li, X., Campos, A., Pomeroy, K., Masliah, E., et al. (2017) . ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating g-secretase activity. Nat. Commun. 8, 1472. (Chishti et al., 2001) . Postnatal day 2-3 WT and TREM2 KO mice were used for primary microglial cultures. Since hormonal effects are negligible at this stage, mixed primary microglial cultures were taken from both males and females. Only 3-4 month old male WT and TREM2 KO mice were used for Ab injection analysis. Only 9-10 month old male TgCRND8 mice were used for analysis. Animal procedures did not include additional drug or treatment regimen other than that described. Mouse lines were housed with littermates with free access to food and water with a 12 hour light/day cycle. All animal procedures, including husbandry were performed under the guidelines of the Institutional Animal Care and Use Committee at Sanford Burnham Prebys Medical Discovery Institute.
Continued
Cell culture models BV2 cells (originating from female mice) and human embryonic kidney (HEK) 293T cells (sex information is not available) were obtained from ATCC and cultured in DMEM containing 10% FBS. Cell lines were authenticated by the providers. BV2 cells stably expressing human TREM2 were generated using lentiviral vectors comprising a PGK promoter upstream of a human TREM2 cDNA-IRES2-EGFP module (GeneCopoeia). Information with respect to previous procedures for human subjects was not disclosed with the tissue samples used. No data were excluded in the experiments described. Detailed information for human samples (gender, age and disease stage) can be found in Table S1 .
Human samples
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METHOD DETAILS
Cell culture and generation of stable cell lines Primary microglial cultures were prepared as described previously (Atagi et al., 2015) . Briefly, brains were removed from WT or TREM2 KO mice at postnatal day 2-3. After removal of the meninges, brains were treated with a Papain Dissociation System (Worthington Biochemical Corporation) according to manufacturer's specifications. Mixed glial cells were plated in flasks coated with poly-D-lysine and grown in DMEM containing 10% FBS (VWR Life Science Seradigm). 25 ng/mL GM-CSF (R&D Systems) was added into the cultures after 5 days and removed before harvesting. Microglial cells were harvested twice by shaking (200 rpm, 60 min) 10-14 days after plating and subjected to various treatments within 24 h of harvest. BV2 and human embryonic kidney (HEK) 293T cells were from ATCC and cultured in DMEM containing 10% FBS. BV2 cells stably expressing human TREM2 were generated using lentiviral vectors comprising a PGK promoter and human TREM2 cDNA-IRES2-EGFP module (GeneCopoeia). Lentiviral particles (Lv-TREM2) were packaged through the viral core at Sanford Burnham Prebys Medical Discovery Institute. BV2 cells were transduced with Lv-TREM2 or control lentivirus (Lv-control) and single EGFP-positive cells were sorted by flow cytometry using a high speed cell sorter (BD Biosciences FACSAriaIIu). Single clonal cell lines were expanded and characterized for expression. To knockdown endogenous mouse TREM2, lentiviruses expressing shRNA specifically targeting mouse TREM2 mRNA (5 0 -CCAGUCCUUGAGGGUGUCAUGUACU -3 0 ) were transduced to BV2 stable cell lines. No mycoplasma contamination was detected in cell lines used in this study.
Ab preparation
Ab monomers and oligomers were prepared as described previously with slight modification . Unlabeled or biotin-labeled synthetic human Ab 1-42 peptides (Anaspec) were dissolved in hydroxyfluroisopropanol (HFIP) and subsequently dried using a SpeedVac system (Thermo Fisher Scientific). Monomers were prepared by dissolving the lyophilized Ab in dimethyl sulfoxide (DMSO) at 2.2 mM, sonicated for 10 min and diluted in PBS to 100 mM. Ab oligomers were prepared in DMSO/PBS and oligomerized by incubation at room temperature (RT) for 48 h. Monomers in the oligomer preparation were removed using Amicon Ultra Centrifugal Filters (Millipore) (10 kDa molecular weight cut-off). Samples from each step were collected and analyzed by immunoblotting. No difference in oligomerization between normal and biotin-Ab was observed.
Carboxyfluorescein (FAM) -Ab aggregates were prepared as described previously (Kleinberger et al., 2014) . Briefly, FAM-Ab 1-42 peptides (Anaspec) were dissolved in trifluoroacetic acid, lyophilized using a SpeedVac, and dissolved in DMSO/ PBS to 100 mM at 37 C overnight.
Immunoprecipitation assay and Ab ELISA In cell-free binding assays, 0.5 mg human IgG1 Fc, TREM2-Fc or TREM1-Fc (R&D Systems) was incubated with 0.25 mg unlabeled or biotin-labeled Ab monomer or oligomers in TBS buffer (25 mM Tris-HCl pH 7.6, 150 mM sodium chloride) containing 0.05% Tween-20 (TBST) and Dynabeads protein G (Thermo Fisher Scientific) at 4 C for 2 h. Beads were then washed with TBST four times and boiled in SDS-PAGE loading buffer (BioPioneer) containing 62.6 mM Tris-HCl (pH 6.8), 2% SDS, 0.01% bromophenol blue, 10% glycerol and 0.5M dithiothreitol and subjected to immunoblot analysis. No difference in TREM2 binding between unlabeled and biotin-labeled Ab was observed (data not shown). These experiments were repeated 5 times. Randomization procedures are not applicable to these experiments. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Endogenous Ab/TREM2 interactions were determined using brain tissues from TgCRND8 APP transgenic mice (9-month old) or from human AD patients. Tissues or cells were lysed in TBS containing 5 mM ethylenediaminetetraacetic acid (EDTA), 1% Nonidet P40 substitute (T-DET O-9) with protease inhibitors (Roche), and incubated with TREM2 antibodies (rat anti-TREM2 antibody for TgCRND8 samples, MABN755, Millipore; rabbit anti-human TREM2 antibody for human brain samples, 91068, Cell Signaling Technology) / Dynabeads protein G at 4 C overnight. Beads were washed four times in TBST and boiled in SDS-PAGE loading buffer or a buffer containing 0.2% SDS and 0.1% Tween-20. Samples were analyzed by immunoblotting or enzyme-linked immunosorbent assay (ELISA) using a human Ab 1-42 ELISA kit (Thermo Fisher Scientific). Human Ab was undetectable in our IP-ELISA assays from wild-type (WT) mouse brain (data not shown), confirming specific detection of human Ab using this IP-ELISA detection method. Randomization procedures are not applicable to these experiments. Data were collected from 3 experiments (5 samples from TgCRND8 mice, 6 samples from human AD patients) and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Solid phase binding assay Human IgG1 Fc, TREM2-Fc, TREM1-Fc, CD36-Fc, RAGE-Fc proteins (R&D systems), or TREM2-Fc proteins (WT and mutants) purified in-house were coated onto Nunc MaxiSorp 96-well plates (Thermo Fisher Scientific) at 0.2 mg/well in TBS at 4 C overnight. After blocking in 5% non-fat milk in TBS for 2h at room temperature, biotin-Ab oligomers equivalent to 6.25, 12.5, 25, 50, 100, or 200 nM Ab monomers were added to the plates at 4 C overnight. Plates were washed with TBS containing 0.05% Tween-20 (TBST, Sigma) four times and incubated with streptavidin-HRP (1:5000, Thermo Fisher Scientific) for 30 min at RT. Plates were then washed with TBST three times, developed in TMB solution (Thermo Fisher Scientific) , and absorbance at 450 nM was measured using a Synergy H1 microplate reader (BioTek). Similar to the above, 0.1 mg biotin-Ab oligomers were immobilized on plates and incubated with 6.25, 12.5, 25, 50, 100, or 200 nM human IgG1 Fc, TREM2-Fc, TREM1-Fc, CD36-Fc or RAGE-Fc. Bound Fc proteins were detected by anti-human IgG-HRP (1:5000, Thermo Fisher Scientifc) and developed in TMB solution as described.
These experiments were repeated 3 times. Randomization procedures are not applicable to these experiments. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Generation of TREM2-Fc proteins cDNA comprising the human TREM2 extracellular region (1-174 amino acids) was cloned into pFUSE-hIgG1-Fc (Invivogen). R47H and R62H TREM2-Fc mutant vectors were generated using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies), following the manufacturer's recommendations. Fc vectors were transfected into HEK293T cells with Lipojet (Version 2, SignaGen Laboratories). TREM2-Fc proteins were collected in serum-free DMEM and purified with protein A/G beads (Thermo Fisher Scientific), followed by elution in 0.2M glycine pH 2.8, neutralization and dialysis. Protein yields were subsequently determined by BCA protein assay.
Immunoblotting Prepared samples were subjected to gel electrophoresis (4%-20% SDS-PAGE, Bio-Rad laboratories) and probed using relevant antibodies. The following primary antibodies were used for immunoblot: mouse monoclonal antibody against Ab 1-12 (B436) (Huang et al., 2016) , rabbit monoclonal antibody against human TREM2 (clone D814C, 91068, Cell Signaling Technology) (Ma et al., 2016) , goat anti-human TREM2 antibody (AF1828, R&D Systems), sheep anti-mouse TREM2 antibody (AF1729, R&D Systems), mouse monoclonal c-Myc tag antibody (13-2500, Thermo Fisher Scientific), mouse monoclonal antibody for Gas6 (clone A-9, sc-376087, Santa Cruz Biotechnology), rabbit monoclonal antibody against DAP12 (Clone D7G1X, 12492, Cell Signaling Technology) rabbit monoclonal antibody for phospho-SYK (clone F.724.5, MA5-14918, Thermo Fisher Scientific), rabbit monoclonal antibody for SYK (Clone D3Z1E, 13198, Cell Signaling Technology) , and mouse monoclonal antibody against b-actin (Clone AC-74, A2228, Sigma). To reduce IgG signals in immunoprecipitates, TrueBlot secondary antibodies against mouse, goat, or rabbit IgG were used (Rockland). These experiments were repeated 3-5 times (see details in the Figure Legends) . Randomization procedures are not applicable to these experiments. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Affinity measurement with Bio-Layer Interferometry (BLI) and Surface Plasmon Resonance (SPR) BLI was performed using the Octet system 8-channel Red96 system (Pall Life Sciences). SA biosensors and kinetics buffer were purchased from Pall Life Sciences. Biotin-Ab oligomers were immobilized onto SA biosensors and incubated with varying concentrations (2.74 nM to 222 nM) of TREM2-His or TREM1-His proteins in solution. The experiments included five steps: (i) biotin-Ab oligomers loading onto SA biosensors (240 s); (ii) baseline (10 s); (iii) association of TREM2-His or TREM1-His for measurement of K on (120 s); and (iv) dissociation of Ab oligomers for the measurement of K dis (600 s). Baseline and dissociation steps were conducted in 1 3 kinetics buffer and background subtraction was used to correct for biosensor drifting. Background wavelength shifts were measured from reference biosensors that were loaded only with biotin-Ab oligomers. All experiments were performed at 30 C with shaking at 1,000 rpm. ForteBio's data analysis software 7.0 was used to fit the data to a 1:1 binding model. SPR was determined using Biacore T100 instrument (GE Health). TREM2-Fc (20 mg/ml) was captured on the GAH (goat anti-human) IgG immobilized CM5 sensor surface. Binding of a dilution series comprising biotin-Ab oligomers (16 nM to 1000 nM) to TREM2-Fc was analyzed and fitted to the 1:1 binding model using BIAevaluation software.
These experiments were repeated 3 times. Randomization procedures are not applicable to these these assays. No statistical methods were used for sample size estimation. No data were excluded.
Cell surface Ab binding assay Cells were incubated with 200 nM biotin-Ab oligomers or FAM-Ab aggregates at 4 C for 2 h. Cells were then washed five times with cold PBS and fixed in 4% PFA without permeabilization. Cell surface bound Ab was detected using a streptavidin-Alexa Fluor 555 conjugate (1:500, Thermo Fisher Scientific) or directly subjected to confocal imaging. Bound Ab was analyzed using IMARIS. At least 400 cells for each group were analyzed from 3-5 independent experiments. Randomization procedures are not applicable to these experiments. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Ab phagocytosis and degradation assay
To determine the effect of TREM2 deletion on Ab phagocytosis, primary microglial cultures from WT or TREM2 KO mice were incubated with FAM-Ab (200 nM) for 30 min, 1 h or 2 h. Following the removal of FAM-Ab, cells were trypsinized, washed with cold PBS and subjected to flow cytometry analysis using a LSRFortessa X-20 cell analyzer (BD Biosciences). Surface bound FAM-Ab was quenched by incubation with 0.4% trypan blue in PBS (pH 4.4) for 1 min prior to FACS analysis.
For Ab degradation, cells were washed three times with DMEM 2 h after FAM-Ab or unlabeled Ab oligomers phagocytosis and cultured for an additional 2 or 4 hours (in Ab-free media), and analyzed by flow cytometry or ELISA analysis at varying time points. Alternatively, cells with FAM-Ab were fixed in 4% paraformaldehyde (PFA) and visualized using an LSM 710 confocal microscope (ZEISS). FAM-Ab intensity was analyzed and quantified using IMARIS software (Bitplane). At least 500 cells from each group were analyzed from three independent experiments. These experiments were repeated 3 times. Randomization procedures are not applicable to these experiments. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Gas6 degradation assay
Recombinant Gas6 protein (R&D systems) was labeled with Alexa Fluor 488 microscale protein labeling kit following manufacturer's instructions. Primary microglial cultures from WT or TREM2 KO mice were incubated with fluorescent-labeled Gas6 (100 nM) for 2 h. Following the removal of Gas6, cells were washed three times and cultured for an additional 4 or 22 hours and analyzed by flow cytometry using a LSRFortessa X-20 cell analyzer (BD Biosciences). Surface bound fluorescent-labeled Gas6 was quenched by incubation with 0.4% trypan blue in PBS (pH 4.4) for 1 min prior to FACS analysis.
These experiments were repeated 3 times. Randomization procedures are not applicable to this assay. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Electrophysiology
Treated microglia cells were recorded under voxltage clamp conditions. Patch pipettes with a tip resistance of 5-8 MU were pulled from borosilicate glass capillaries (B150-86-10, Sutter) using a laser micropipette puller (P-2000, Sutter) . Patch pipettes were filled with an intracellular solution of the following composition (in mM): K-gluconate 123, KCl 6, CaCl 2 1, MgCl 2 4.6, EGTA 10, HEPES 10, Na 2 -GTP 0.4, Na 2 -ATP 4.0, pH 7.24 adjusted with KOH. The extracellular recording solution comprised of Hank's balanced salt solution (HBSS, 14025, GIBCO) supplemented with 10 mM HEPES, 5 mM glucose and adjusted to pH 7.4 with NaOH. A series of hyperpolarizing voltage steps from À60 mV to À160 mV (D = 10 mV) were applied using a computer-controlled patch-clamp amplifier (Axopatch 200B, Molecular Devices) connected to an analog to digital converter (Digidata 1322A, Molecular Devices). To block Kv1.3 or Kir 3.1 channel, cells were incubated for 1 h with 400 pM Margatoxin or 100 nM Tertiapin (Alomone, Israel), respectively. Whole-cell capacitance was measured under voltage clamp configuration by applying a 5 mV pulse from a membrane potential of À60 mV. Electrophysiological recordings were taken from 4 independent microglial cultures. Randomization procedures are not applicable to this assay. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Quantitative real-time (qRT) -PCR Total RNA was purified from cells using the RNeasy Universal Mini Kit (QIAGEN) following manufacturer's specifications. Purified RNA was then transcribed to cDNA using the SuperScript III Reverse Transcriptase system (Thermo Fisher Scientific), and subjected to qPCR reactions using the FastStart Universal SYBR Green Master (Rox) system (Roche) with primers targeting hTREM2, mTREM2, mouse GAPDH, These experiments were repeated 3 times. Randomization procedures are not applicable to this assay. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Multiplex cytokine ELISA assay Primary microglial cells were treated with 0, 0.2 mM or 1 mM Ab oligomers for 24h or 48h. Conditioned medium was collected and analyzed using a mouse cytokine multiplex kit (Quansys), following the manufacturer's recommendations. Cytokine measurements falling under the detection threshold (below lower limits of the standard curve) are not presented. These experiments were repeated 3 times. Randomization procedures are not applicable to this assay. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded.
Fluorescence resonance energy transfer (FRET) assay
FRET experiments were performed as previously described (Zhu et al., 2017) . Briefly, average of fluorescence intensities of the donor before and after bleaching was calculated from the measurement of 6 cells in three independent experiments per group. Randomization procedures are not applicable to this assay. Data were collected and analyzed in a double-blind fashion. No statistical methods were used for sample size estimation. No data were excluded. FRET efficiency was calculated by E fret = 1À(I a /I b ), where I a and I b represents the steady-state donor fluorescence with or without the acceptor, respectively.
Stereotaxic injections
Stereotaxic injections were performed as described previously with modifications (Wang et al., 2014; Zhao et al., 2015) . Random WT or TREM2 KO mice (4-5 month old) were anesthetized using 2% isoflurane, and Ab oligomers (5 mg in 2 mL vehicle/side) or control vehicle (PBS containing 4% DMSO) were injected bilaterally into the hippocampus at the following coordinates: anterior posterior, À2.2 mm; medial lateral, ± 1.5 mm; dorsal ventral, À1.8 mm using an automated stereotaxic injection apparatus (Model 940, KOPF). Mice were sacrificed and analyzed 3 days after injection.
For migration analysis, FAM-Ab aggregates or control vehicle were injected unilaterally into the hippocampus and cortex at the following coordinates: anterior posterior, À2 mm; medial lateral, ± 1.5 mm; dorsal ventral, À2 and À1 mm (Mazaheri et al., 2017) . Mice were sacrificed and analyzed 16 hours after injection.
Immunohistological analysis
Mice were anesthetized with 4% isoflurane and intracardially perfused with PBS. Brain tissues were harvested and fixed in 4% paraformaldehyde at 4 C for 24 h. Tissues were washed in PBS and cryoprotected in PBS containing 30% sucrose. Tissues were embedded in OCT containing 30% sucrose (at 1:1 v/v) and free-floating coronal brain cryostat sections (25 mm) were collected. Data were collected and analyzed in a double-blind fashion. For Ab detection, brain sections were immunostained with MOAB-2
